✅급여재평가 후유증...레보드로, 약가인하율보다 큰 손실

https://www.dailypharm.com/Users/News/NewsView.html?ID=327530

✅3월 등재 도네페질+메만틴 후발약, 허가신청 잇따라

https://www.dailypharm.com/Users/News/NewsView.html?ID=327539

✅종근당 '텔미트렌·볼그레' 품귀...매출 효자품목 수급불안

https://www.dailypharm.com/Users/News/NewsView.html?ID=327465

✅울트라셋 제네릭, 불순물 초과검출 회수 사례 늘어

https://www.dailypharm.com/Users/News/NewsView.html?ID=327527

✅앱클론 CAR-T 후보, 개발단계 희귀약 지정…신속허가 기대

https://www.dailypharm.com/Users/News/NewsView.html?ID=327501

✅비대면진료 처방금지 비급여 품목 10% 감소...이유는?

https://www.dailypharm.com/Users/News/NewsView.html?ID=327524